This first-in-human randomized clinical trial at Oslo University Hospital, Norway on patients with tuberculosis shows that the vaccine H56:I31 developed by Statens Serum Institut is safe and immunogenic during active tuberculosis disease and could serve as host-directed-therapy to improve prognosis and combat the tuberculosis pandemic
Add important information, links, or images here to describe your project.
Get more citations
OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.
This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information,
and information on cookie use.